Activated leukocyte cell adhesion molecule regulates B lymphocyte migration across central nervous system barriers
- 13 November 2019
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 11 (518)
- https://doi.org/10.1126/scitranslmed.aaw0475
Abstract
The presence of B lymphocyte–associated oligoclonal immunoglobulins in the cerebrospinal fluid is a classic hallmark of multiple sclerosis (MS). The clinical efficacy of anti-CD20 therapies supports a major role for B lymphocytes in MS development. Although activated oligoclonal populations of pathogenic B lymphocytes are able to traffic between the peripheral circulation and the central nervous system (CNS) in patients with MS, molecular players involved in this migration have not yet been elucidated. In this study, we demonstrated that activated leukocyte cell adhesion molecule (ALCAM/CD166) identifies subsets of proinflammatory B lymphocytes and drives their transmigration across different CNS barriers in mouse and human. We also showcased that blocking ALCAM alleviated disease severity in animals affected by a B cell–dependent form of experimental autoimmune encephalomyelitis. Last, we determined that the proportion of ALCAM+ B lymphocytes was increased in the peripheral blood and within brain lesions of patients with MS. Our findings indicate that restricting access to the CNS by targeting ALCAM on pathogenic B lymphocytes might represent a promising strategy for the development of next-generation B lymphocyte–targeting therapies for the treatment of MS.Funding Information
- Fonds de Recherche du Québec - Santé
- Fonds de Recherche du Québec - Santé
- Fonds de Recherche du Québec - Santé
- Multiple Sclerosis Society of Canada
- Multiple Sclerosis Society of Canada
- Multiple Sclerosis Society of Canada
- Canada Research Chairs
- Multiple Sclerosis Society of Canada
- Multiple Sclerosis Society of Canada
- Multiple Sclerosis Society of Canada
This publication has 82 references indexed in Scilit:
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisThe New England Journal of Medicine, 2017
- Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisThe New England Journal of Medicine, 2017
- Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapyScience Translational Medicine, 2015
- B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cellsThe Journal of Experimental Medicine, 2012
- Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trialThe Lancet, 2011
- Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple SclerosisArchives of Neurology, 2010
- Abnormal B‐cell cytokine responses a trigger of T‐cell–mediated disease in MS?Annals of Neurology, 2010
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trialAnnals of Neurology, 2009
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple SclerosisThe New England Journal of Medicine, 2008
- The epidemiology of multiple sclerosis in EuropeEuropean Journal of Neurology, 2006